Regenxbio Inc (RGNX) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Regenxbio Inc stock $6.16, price $7.32, that is 15.8% below the price, quality 41 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Regenxbio Inc
RGNX · USExpensive (fair value 16% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $5.31 – $45.68 · fair‑value band $4.62 – $7.70 · the $7.32 price screens above the $6.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Regenxbio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Show moreShow less
The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies.
Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Stock analysis
Regenxbio Inc (RGNX) currently trades at $7.32, while our estimate is $6.16, 16% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $4.62 (bear) to $7.70 (bull), the price of $7.32 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Regenxbio Inc reported revenue of $170M in FY2025 versus $470M in FY2021, a compound −22.4%/yr. Reported net income was −$194M in FY2025.
Key figures
Market cap $484M Small · P/S ratio 3.27 · EPS (TTM) $−3.20 · Net margin −114% · Return on equity −113% · Return on assets (EBIT) −29.9% (5-year average) · Operating margin −803% · Revenue (TTM) $154M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, RGNX screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director bought shares worth $949,541, on Aug 27, 2026. Over the same period, one person sold shares worth $718,232.
- BuyGregory Austin CiongoliDirector102,603 shares at $9.25$949,541Aug 27, 2026
- SaleSteve PakolaChief Medical Officer4× since Mar 10, 2026: 78,927 shares, avg. $11.91$939,970Jul 2, 202610b5-1 plan
Plus 21 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
- REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
- REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific
- RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
Compare Regenxbio Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs RGNX |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs RGNX |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs RGNX |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs RGNX |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs RGNX |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs RGNX |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs RGNX |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs RGNX |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs RGNX |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs RGNX |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Regenxbio Inc (RGNX) overvalued or undervalued?
What is the fair value of RGNX?
What is the quality score of RGNX?
What is the price target for Regenxbio Inc (RGNX)?
What is the Regenxbio Inc stock forecast for 2026?
What is the revenue of Regenxbio Inc (RGNX)?
What is the intrinsic value of Regenxbio Inc (RGNX)?
Is Regenxbio Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of RGNX?
How much is Regenxbio Inc worth?
What do the bullish and bearish scenarios say about RGNX?
What is the PEG ratio of RGNX?
How solid is the balance sheet of Regenxbio Inc (RGNX)?
How far is RGNX from its 52-week high?
Which stocks are comparable to Regenxbio Inc?
Is Regenxbio Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Regenxbio Inc (RGNX)?
What should I pay attention to with Regenxbio Inc right now?
Key figures of Regenxbio Inc
How large is the market capitalisation of Regenxbio Inc (RGNX)?
What is the P/S ratio of Regenxbio Inc (RGNX)?
What are the earnings per share of Regenxbio Inc (RGNX)?
What is the net margin of Regenxbio Inc (RGNX)?
What is the return on equity of Regenxbio Inc (RGNX)?
What is the EBIT return on assets of Regenxbio Inc (RGNX)?
What is the operating margin of Regenxbio Inc (RGNX)?
How fast is revenue growing at Regenxbio Inc (RGNX)?
How much free cash flow does Regenxbio Inc (RGNX) generate?
How much net cash does Regenxbio Inc (RGNX) hold?
Watch Regenxbio Inc in the live analysis
One click puts Regenxbio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.